**All Interactions with Lamivudine (Epivir)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Lamivudine** | **Effect on Drug Levels** | **Effect on Lamivudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Abacavir[66](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#66),[67](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#67)  (ABC)(Ziagen) | 600 mg x 1 dose | 150 mg x 1 dose | No significant change | Lamivudine Cmax: decreased 35%; AUC: decreased 15% | - | Delayed lamivudine absorption | No dose adjustment necessary |
| Adefovir[263](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#263)  (Hepsera) | 10 mg QD | - | No significant change | - | - | - | No dose adjustment necessary |
| Amprenavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#60)  (APV)(Agenerase) | 150 mg x 1 dose | 150 mg x 1 dose | No significant change | No significant change | - | - | No dose adjustment necessary |
| Atazanavir[106](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#106),  (ATV)(Reyataz) | 400 mg QD x 6 days | 150 mg BID with zidovudine 300 mg BID x 6 days | Not studied | No significant change | - | - | No dose adjustment necessary |
| Buprenorphine[442](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#442)  (Suboxone)(Buprenex) | 14 mg QD | 300 mg QD | No significant change | - | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Lamivudine** | **Effect on Drug Levels** | **Effect on Lamivudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Chlorpropamide[469](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#469)  (others)(Diabinese) | 250 mg x 1 | 150 mg QD x 1 | Chlorpropamide AUC: decreased 45%; Cmax: decreased 30% | - | Potentially increased serum glucose concentrations | - | Consider alternative agent  *Alternative Agents*:  **Glyburide, glipizide, metformin** |
| Co-trimoxazole[332](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#332),[333](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#333)  (TMP/SMX, Trimethoprim/Sulfamethoxazole)(Bactrim, Septra) | 160 mg/800 mg QD x 5 days | 300 mg QD x 1dose | Not studied | Lamivudine AUC: increased 44% | Increased lamivudine effects | - | No dose adjustment necessary |
| Efavirenz[90](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#90)  (EFV)(Sustiva) | 600 mg x 14 days | 150 mg Q12H x 14 days | Not studied | No significant change | - | - | No dose adjustment necessary |
| Entecavir[391](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#391)  (Baraclude) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| Indinavir[16](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#16)  (IDV)(Crixivan) | 800 mg Q8H x 1 week | 150 mg BID x 1 week | No significant change | No significant change | - | - | No dose adjustment necessary |
| Methadone[202](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#202)  (Dolophine)(Dolophine) | - | 150 mg lamivudine/300 mg zidovudine (combination tablet) | No significant effect | Not studied | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Lamivudine** | **Effect on Drug Levels** | **Effect on Lamivudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Nelfinavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#24)  (NFV)(Viracept) | 750 mg Q8h x 7-10 days | 150 mg x 1 dose | Not studied | Lamivudine AUC: no significant change; Cmax: increased 31% | Increased lamivudine effects | - | No dose adjustment necessary |
| Ribavirin[236](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#236)  (Rebetol, Virazole) | 800 mg QD | 150 mg BID | - | No significant change | - | - | No dose adjustment necessary |
| Stavudine[86](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#86)  (d4T)(Zerit) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| Tenofovir disoproxil fumarate[96](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#96),[97](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#97)  (TDF)(Viread) | 300 mg QD x 7 days | 150 mg BID x 7 days | No significant change | Lamivudine Cmax: decreased 24% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#154)  (TPV)(Aptivus) | 1250 mg BID with 100 mg ritonavir BID x 42 doses | 150 mg BID x 43 doses | - | Lamivudine Cmax: decreased 29% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#154)  (TPV)(Aptivus) | 250 mg BID with 200 mg ritonavir BID | 150 mg BID x 43 doses | - | No significant change | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#154)  (TPV)(Aptivus) | 750 mg BID with 100 mg ritonavir BID x 42 doses | 150 mg BID x 43 doses | - | No significant change | - | - | No dose adjustment necessary |
| Zidovudine[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=18&post=4#81)  (AZT, ZDV)(Retrovir) | - | - | Zidovudine Cmax: increased 39% | No significant change | Increased zidovudine effects | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 16: | Crixivan [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; Oct 2005. |
| 24: | Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004. |
| 60: | Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004. |
| 66: | Ziagen [package insert]. Research Triangle Park, NC: GlaxoWellcome Inc.; Sept 2005. |
| 67: | Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 1999;43:1708-15. |
| 81: | Retrovir [package insert]. Research Triangle Park, NC: GlaxoWellcome; Sept 2005. |
| 86: | Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb Immunology; Sept 2005. |
| 90: | Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Dec 2011. |
| 96: | Viread [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2006. |
| 97: | Kearney B, Flaherty J, Sayre J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and lamivudine or didanosine [abstract #337]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina. |
| 106: | Mummaneni V, Randall D, Geraldes M, et al. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with lamivudine (3TC) and zidovudine (ZDV) in healthy subjects. [abstract #H-1713]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois. |
| 154: | Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 202: | Rainey PM, Friedland GH, Snidow JW, et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am J Addictions 2002;11:66-74. |
| 236: | Gries J-M, Torriani FJ, Rodriguez-Torres M, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV co-infection: final results of a randomized clinical study [abstract #136LB]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 263: | Hepsera [package insert]. Foster City, CA: Gilead Sciences, Inc. 2002. |
| 332: | Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996;59:550-58. |
| 333: | Epivir [package insert]. Research Triangle Park, NC: GlaxoWellcome; Nov 2005. |
| 391: | Baraclude [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2005. |
| 442: | Gruber VA, Baker J, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors didanosine, lamivudine and tenofovir [abstract A1-1306]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California. |
| 469: | Bakare-Odunola MT, Enemaili I, Garba M, et al. The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects. Eur J Drug Metab Pharmacokinet 2008; 33: 165-71. |